Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial



Status:Enrolling by invitation
Conditions:Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/28/2019
Start Date:April 28, 2016
End Date:July 2024

Use our guide to learn which trials are right for you!

A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

The purpose of the study is to provide access to continued treatment for subjects who
participated in other Astellas sponsored ASP2215 trials that completed the primary analysis
and for whom the Investigator feels may have potential to continue to derive clinical benefit
from the treatment with ASP2215, and who did not meet any of the study discontinuation
criteria in the present study.


Inclusion Criteria:

- Subject must currently be participating in an Astellas sponsored, single agent ASP2215
trial, receiving ASP2215 and have not met any discontinuation criteria of the parent
study and can enroll into this rollover study without interruption of study drug, or
with no more than 2 weeks interruption in study drug.

- Subject must be deriving benefit from continued treatment without any persistent
intolerable toxicity from continued treatment of ASP2215.

- Female subject must either:

- Be of non-childbearing potential: post-menopausal (defined as at least 1 year
without any menses) prior to Screening, or documented surgically sterile or
post-hysterectomy (at least 1 month prior to Screening)

- Or, if of childbearing potential, Agree not to try to become pregnant during the
study and for 180 days after the final study drug administration; And have a
negative urine pregnancy test at Day 1; And, if heterosexually active, agree to
consistently use two forms of highly effective birth control (at least one of
which must be a barrier method) starting at Screening and throughout the study
period and for 180 days after the final study drug administration.

- Female subject must agree not to breastfeed starting at Screening and throughout the
study period, and for 60 days after the final study drug administration.

- Female subject must not donate ova starting at Screening and throughout the study
period, and for 180 days after the final study drug administration.

- Male subject and their female spouse/partners who are of childbearing potential must
be using highly effective contraception consisting of two forms of birth control (at
least one of which must be a barrier method) starting at Screening and continue
throughout the study period, and for 120 days after the final study drug
administration.

- Male subject must not donate sperm starting at Screening and throughout the study
period and, for 120 days after the final study drug administration.

- Subject agrees not to participate in another interventional study while on treatment.

Exclusion Criteria:

- Subject requires treatment with concomitant drugs that are strong inducers of
cytochrome P450 (CYP)3A.

- Subject requires treatment with concomitant drugs that target serotonin
5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or
sigma nonspecific receptor with the exception of drugs that are considered absolutely
essential for the care of the subject.

- Subject requires treatment with concomitant drugs that are strong inhibitors or
inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered
absolutely essential for the care of the subject.
We found this trial at
6
sites
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Baltimore, Maryland 21205
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cleveland, Ohio 44106
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
?
mi
from
Hershey, PA
Click here to add this to my saved trials
New York, New York 10032
?
mi
from
New York, NY
Click here to add this to my saved trials
Phoenix, Arizona 85014
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials